Home › Research › Biomarkers
Performance of plasma p-tau217 and NfL in an unselected memory clinic setting
Rebecca Z Rousset, Thomas Claessen, Argonde C van Harten, Afina W Lemstra, Yolande A L Pijnenburg, Wiesje M van der Flier, Anouk den Braber, Andreas Jeromin et al.. Alzheimer's & dementia (Amsterdam, Netherlands), 2024-11-23
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
p-Tau217 levels were highest in patients with Alzheimer's disease (AD) dementia, whereas NfL levels were highest in patients with frontotemporal dementia (FTD). Low p-tau217/low NfL was associated mostly with non-neurological diagnoses (79%), and high p-tau217/low NfL indicated AD pathology at any stage (84%). Low p-tau217/high NfL indicated FTD (38%) and high p-tau217/high NfL indicated AD dementia (87%). p-Tau217 can identify AD pathology at any disease stage. NfL can differentiate FTD from other diagnoses (e.g., AD dementia). Plasma p-tau217 and NfL can support clinical decision-making, and we suggest using them as complements to standard clinical assessment. HIGHLIGHTS: Phosphorylated tau-2017 (p-tau217) can detect Alzheimer's disease (AD) across the clinical continuum.Neurofilament light (NfL) can differentiate frontotemporal dementia (FTD) from other diagnoses (AD dementia, dementia with Lewy bodies [DLB], and Psychiatry).p-Tau217 may detect AD co-pathology in other diseases or dementia types (e.g., DLB).p-Tau217 and NfL show potential for clinical implementation.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rousset, R. Z., Claessen, T., van Harten, A. C., Lemstra, A. W., Pijnenburg, Y. A. L., van der Flier, W. M., et al. (2024). Performance of plasma p-tau217 and NfL in an unselected memory clinic setting. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.70003
Vancouver
Rousset RZ, Claessen T, van Harten AC, Lemstra AW, Pijnenburg YAL, van der Flier WM, et al. Performance of plasma p-tau217 and NfL in an unselected memory clinic setting. Alzheimer's & dementia (Amsterdam, Netherlands). 2024. doi:10.1002/dad2.70003. PMID: 39583647.
BibTeX
@article{rousset2024-39583647,
author = {Rousset, Rebecca Z and Claessen, Thomas and van Harten, Argonde C and Lemstra, Afina W and Pijnenburg, Yolande A L and van der Flier, Wiesje M and den Braber, Anouk and Jeromin, Andreas and others},
title = {{Performance of plasma p-tau217 and NfL in an unselected memory clinic setting}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2024},
doi = {10.1002/dad2.70003},
pmid = {39583647},
url = {https://doi.org/10.1002/dad2.70003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- p-Tau217 levels were highest in patients with Alzheimer's disease (AD) dementia, whereas NfL levels were highest in patients with frontotemporal dementia (FTD).
- Low p-tau217/low NfL was associated mostly with non-neurological diagnoses (79%), and high p-tau217/low NfL indicated AD pathology at any stage (84%).
- Low p-tau217/high NfL indicated FTD (38%) and high p-tau217/high NfL indicated AD dementia (87%). p-Tau217 can identify AD pathology at any disease stage.
- NfL can differentiate FTD from other diagnoses (e.g., AD dementia).
- Plasma p-tau217 and NfL can support clinical decision-making, and we suggest using them as complements to standard clinical assessment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthModerate
How this study scored 50/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 28 of the 56 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39583647) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 28 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 28 of the 56 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.